| Cover | Jan. 10, 2025 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jan. 10, 2025 |
| Entity File Number | 001-41157 |
| Entity Registrant Name | Neuphoria Therapeutics Inc. |
| Entity Central Index Key | 0001191070 |
| Entity Tax Identification Number | 99-3845449 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 100 Summit Dr |
| Entity Address, City or Town | Burlington |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 01803 |
| City Area Code | +1 |
| Local Phone Number | 781 439 5551 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.00001 par value per share |
| Trading Symbol | NEUP |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |
